Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Intas launches biosimilar version of Rituximab
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Refining diagnosis of multiple sclerosis with revised MRI criteria.
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
RTL therapy for multiple sclerosis: a Phase I clinical study.
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Novantrone (mitoxantrone HCl) Injection February 2009
Adaptive myelination from fish to man.
Breastfeeding and multiple sclerosis.
Immune competence after alemtuzumab treatment of multiple sclerosis.
One can prevent post-partum MS relapses by exclusive breast feeding: no.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Architecture of human mTOR complex 1.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014

Pages